Adalvo, in collaboration with CNX Therapeutics, has launched Pregabalin Extended-Release (ER) tablets in the United Kingdom, strengthening its position as the first and only company to introduce this value-added formulation across Europe, following successful launches in Germany, Spain, and the Baltics.
Pregabalin ER is indicated for neuropathic pain, offering a prolonged-release formulation that reduces dosing frequency, improving adherence and overall treatment compliance. With nearly 10% of the UK population affected by neuropathic pain, this advancement provides a meaningful option for both patients and healthcare providers.
The European market for Pregabalin products reached $757 million in sales in 2023 (IQVIA), reflecting strong demand for effective neuropathic pain treatments.
"Being first and only to market with Pregabalin ER in Europe highlights our strength in delivering high-value, differentiated treatments," says Anil Okay, CEO of Adalvo. "This launch reflects our agility and market expertise, ensuring high-quality differentiated solutions for patients and partners."
Guy Clark, CEO of CNX Therapeutics, adds: "The launch of Pregabalin ER marks an important milestone in our commitment to addressing unmet needs for patients and prescribers. By offering a once-daily formulation, we aim to provide healthcare professionals with a valuable tool to help improve patient outcomes in the management of neuropathic pain."
Building on this momentum, Adalvo is set to expand Pregabalin ER into additional key European markets.
Partner with Adalvo today.